HIGHLIGHTS
- who: Anil Negi from the University of Groningen have published the research work: University of Groningen, in the Journal: (JOURNAL) of November/15,/2021
- what: The authors report the cohort "Olaparib for BRCA1/2 mutated tumors." often only based on the presence of a germline BRCA mutation, and lacking detailed biomarker information such as confirmation of biallelic BRCA LoF in tumor tissue.
- how: The study is conducted in accordance with the International Conference of Harmonization of Good Clinical Practice and the Declaration of Helsinki and was approved by the independent ethics committee and . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.